/ Source: The Associated Press
Drug maker Merck & Co. said Wednesday the U.S. Food and Drug Administration has designated for priority review its supplemental application for Gardasil's potential use in women aged 27 to 45.
The FDA generally reviews applications designated as "priority" within six months, rather than the standard 10 months.
Gardasil is a vaccine that helps protect against certain diseases, such as cervical cancer, caused by human papillomavirus, or HPV, a common, sexually-transmitted virus. The vaccine is currently approved for girls and women aged 9 through 26.
